Anti-fibrotics in inflammatory bowel diseases: Challenges and successes
- PMID: 39521606
- DOI: 10.1016/bs.apha.2024.10.012
Anti-fibrotics in inflammatory bowel diseases: Challenges and successes
Abstract
Stricture formation leading to obstruction in Crohn's disease (CD) remains one of the largest unmet needs in the field of inflammatory bowel diseases (IBD). Despite this need no selective anti-stricture drug has been approved for use in CD patients. This contrasts with other fibrotic diseases, such as in the lung, liver or kidney, where multiple drug development programs crossed the starting line and two anti-fibrotics are now being approved for pulmonary fibrosis. Strictures are composed of a mix of inflammation, excessive deposition of extracellular matrix (ECM) and smooth muscle hyperplasia, likely all ultimately being responsible for the luminal narrowing driving patient symptoms. Our understanding of the pathogenesis of stricturing CD has evolved and indicates a multifactorial process involving immune and non-immune cells and their soluble mediators. This understanding has rendered target pathways for anti-stricture drug development. Significant progress was made in creating consensus definitions and tools to enable clinical trials with two clinical development programs having been conceived to date. In this chapter, we discuss stricture pathogenesis with a focus on the pathways being tested in clinical trials, and clinical trial endpoints developed for this indication.
Keywords: Extracellular matrix; Intestinal fibrosis; Stenosis.
Copyright © 2024. Published by Elsevier Inc.
Similar articles
-
Fibrosis in IBD: from pathogenesis to therapeutic targets.Gut. 2024 Apr 5;73(5):854-866. doi: 10.1136/gutjnl-2023-329963. Gut. 2024. PMID: 38233198 Review.
-
Intestinal fibrosis: ready to be reversed.Curr Opin Gastroenterol. 2017 Jul;33(4):239-245. doi: 10.1097/MOG.0000000000000363. Curr Opin Gastroenterol. 2017. PMID: 28402994 Free PMC article. Review.
-
Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.Physiol Rev. 2022 Apr 1;102(2):605-652. doi: 10.1152/physrev.00005.2021. Epub 2021 Sep 27. Physiol Rev. 2022. PMID: 34569264 Free PMC article. Review.
-
Novel mechanisms and clinical trial endpoints in intestinal fibrosis.Immunol Rev. 2021 Jul;302(1):211-227. doi: 10.1111/imr.12974. Epub 2021 May 16. Immunol Rev. 2021. PMID: 33993489 Free PMC article. Review.
-
Preventing fibrosis in IBD: update on immune pathways and clinical strategies.Expert Rev Clin Immunol. 2024 Jul;20(7):727-734. doi: 10.1080/1744666X.2024.2330604. Epub 2024 Mar 21. Expert Rev Clin Immunol. 2024. PMID: 38475672 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
